Lupin announced the launch of Abacavir sulfate, Lamivudine, and Zidovudine Tablets, the generic version of ViiV Healthcare‘s Trizivir. Trizivir is a combination of three nucleoside analogues (reverse transcriptase inhibitors) indicated for the treatment of HIV-1 infection.
Abacavir is converted by cellular enzymes to CBV-TP, which inhibits the activity of HIV-1 reverse transcriptase by competing with dGTP and by incorporating into viral DNA. Lamivudine is phosphorylated to 3TC-TP, which inhibits reverse transcriptase via DNA chain termination after incorporation of the nucleotide analogue. Zidovudine is phosphorylated to ZDV-TP, which inhibits reverse transcriptase by DNA chain termination after incorporation of the nucleotide analogue.
Lupin’s Abacavir sulfate, Lamivudine, and Zidovudine Tablets are available in a 300mg/150mg/300mg strength.
For more information call (866) 587-4617 or visit Lupinpharmaceuticals.com.